(chroman-5-yloxy)-acetic acid methyl ester | 600176-40-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (chroman-5-yloxy)-acetic acid methyl ester
• 英文别名: methyl 2-(3,4-dihydro-2H-chromen-5-yloxy)acetate
• CAS: 600176-40-7
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: SNBNYSIKHQZBJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  341.3±30.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (chroman-5-yloxy)-acetic acid methyl ester 在 lithium hydroxide 、 sodium tetrahydroborate 、 溴 、 caesium carbonate 、 sodium bromide 、 1,4-二巯基-2,3-丁二醇 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 生成 {8-[4-(4-Trifluoromethyl-benzyloxy)-benzylsulfanyl]-chroman-5-yloxy}-acetic acid
  参考文献：
  名称：

  Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) δ agonists

  摘要：

  A series of 1,4-benzyloxybenzylsulfanylaryl carboxylic acids were prepared and their activities for PPAR receptor subtypes (alpha, beta, and gamma) with potential indications for the treatment of dyslipidemia were investigated. Analog 13a displayed the greatest binding affinity (IC50 = 10 nM) and selectivity (120-fold) for PPAR delta over PPAR alpha. Many of the analogs investigated were found to be highly selective for PPAR delta and were dependent on the point of attachment of the substituent. In the 1,4-series, analog 28e was found to be the most potent (IC50 = 1.7 nM) and selective (> 1000-fold) compound for PPAR delta. None of the compounds tested showed appreciable binding affinity for PPAR gamma. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.046
• 作为产物：
  描述：

  溴乙酸甲酯 、 5-羟基色满 在 caesium carbonate 作用下， 以 乙腈 为溶剂， 以2.1 g (68%)的产率得到(chroman-5-yloxy)-acetic acid methyl ester
  参考文献：
  名称：

  Compounds that modulate PPAR activity and methods of preparation

  摘要：

  这项发明揭示了能够改变PPAR活性的化合物。该发明还揭示了这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。本发明还揭示了制备所述化合物的方法。

  公开号：

  US20030207916A1

文献信息

• Compounds that modulate PPAR activity and methods of preparation
  申请人：——

  公开号：US20030207916A1

  公开（公告）日：2003-11-06

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

  这项发明揭示了能够改变PPAR活性的化合物。该发明还揭示了这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。本发明还揭示了制备所述化合物的方法。
• THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY
  申请人：Warner-Lambert Company LLC

  公开号：EP1485091A1

  公开（公告）日：2004-12-15
• US6833380B2
  申请人：——

  公开号：US6833380B2

  公开（公告）日：2004-12-21
• [EN] THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY<br/>[FR] DERIVES DE THIAZOLE ET D'OXAZOLE QUI MODULENT L'ACTIVITE DU RECEPTEUR PPAR
  申请人：WARNER LAMBERT CO

  公开号：WO2003074052A1

  公开（公告）日：2003-09-12

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
• Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) δ agonists
  作者：Larry D. Bratton、Gary F. Filzen、Andrew Geyer、Jennifer K. Hoffman、Gina Lu、Jim Pulaski、Bharat K. Trivedi、Paul C. Unangst、Xiangyang Xu

  DOI：10.1016/j.bmcl.2007.04.046

  日期：2007.7

  A series of 1,4-benzyloxybenzylsulfanylaryl carboxylic acids were prepared and their activities for PPAR receptor subtypes (alpha, beta, and gamma) with potential indications for the treatment of dyslipidemia were investigated. Analog 13a displayed the greatest binding affinity (IC50 = 10 nM) and selectivity (120-fold) for PPAR delta over PPAR alpha. Many of the analogs investigated were found to be highly selective for PPAR delta and were dependent on the point of attachment of the substituent. In the 1,4-series, analog 28e was found to be the most potent (IC50 = 1.7 nM) and selective (> 1000-fold) compound for PPAR delta. None of the compounds tested showed appreciable binding affinity for PPAR gamma. (c) 2007 Elsevier Ltd. All rights reserved.